Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
Cheap — but check the trap first.
It looks undervalued, but something is deteriorating. Cheap for a reason, or a real bargain?
Price against fair value
Free cash flow — 10-year history ($B)
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
The read — lights & verdict
- Good:UndervaluedFair value ~$103 vs $67 — a margin of safety of 54%.
- Good:Price is in line with its recordPriced for ~0%/yr, roughly what it has delivered (2.4%/yr).
- Warning:Revenue shrinkingDown 0.2% last year — cheap may mean broken.
- Good:Cash flow compoundingFree cash flow up ~2.4%/yr — the engine is growing.
- Caution:Manageable net debtNet debt of $35B — about 2.7× annual free cash flow. Normal for a mature company.
How this was built. Every figure is computed from Bristol-Myers Squibb Company's SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. We subtract net debt from the value of the business — for Bristol Myers Squibb that is about $35B, or $17 per share. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $66.82 taken 2026-09-04 (Google Finance, manual entry, 2026-08-28) — it is not live and does not move during the day.
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →